Trial Outcomes & Findings for CAVATAK (CVA21) in Non-muscle Invasive Bladder Cancer (VLA-012 CANON) (NCT NCT02316171)

NCT ID: NCT02316171

Last Updated: 2022-07-27

Results Overview

Number of Participants with Treatment-emergent adverse events. The events for each cohort of dose of CVA21 only are pooled for the analysis.

Recruitment status

COMPLETED

Study phase

PHASE1

Target enrollment

16 participants

Primary outcome timeframe

30 days from last dose

Results posted on

2022-07-27

Participant Flow

9 patients were enrolled into VLA012A and 6 patients into VLA012B and data presented for these 15 patients. One patient was enrolled, but not treated due to difficulties in placing the urinary catheter.

Participant milestones

Participant milestones
Measure
A1 - CVA21 1x10^8 TCID50
CAVATAK was administered by intravesical instillation at 1x10\^8 TCID50.
CVA21/Mitomycin C
Mitomycin C (MMC) was administered at 10 mg by intravesical instillation on Day 1. Four hours after instillation of MMC, CVA21 was administered by intravesical instillation of one of 2 ascending dose levels or schedules. Subjects received a second instillation of CVA21 alone on Day 2 without pretreatment with MMC.
A2 - CVA21 3x10^8 TCID50.
CAVATAK was administered at 3x10\^8 TCID50
A3 - CVA21 3x10^8 TCID50 x2
CAVATAK was administered at 3x10\^8 TCID50 twice.
Overall Study
STARTED
4
6
3
3
Overall Study
COMPLETED
3
6
3
3
Overall Study
NOT COMPLETED
1
0
0
0

Reasons for withdrawal

Reasons for withdrawal
Measure
A1 - CVA21 1x10^8 TCID50
CAVATAK was administered by intravesical instillation at 1x10\^8 TCID50.
CVA21/Mitomycin C
Mitomycin C (MMC) was administered at 10 mg by intravesical instillation on Day 1. Four hours after instillation of MMC, CVA21 was administered by intravesical instillation of one of 2 ascending dose levels or schedules. Subjects received a second instillation of CVA21 alone on Day 2 without pretreatment with MMC.
A2 - CVA21 3x10^8 TCID50.
CAVATAK was administered at 3x10\^8 TCID50
A3 - CVA21 3x10^8 TCID50 x2
CAVATAK was administered at 3x10\^8 TCID50 twice.
Overall Study
difficulties with urinary catheter
1
0
0
0

Baseline Characteristics

CAVATAK (CVA21) in Non-muscle Invasive Bladder Cancer (VLA-012 CANON)

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
CVA21
n=9 Participants
CVA21 was administered by intravesical instillation of one of 3 ascending dose levels or schedules:
CVA21/MitomycinC
n=6 Participants
Mitomycin C (MMC) was administered at 10 mg by intravesical instillation on Day 1. Four hours after instillation of MMC, CVA21 was administered by intravesical instillation of one of 2 ascending dose levels or schedules. Subjects received a second instillation of CVA21 alone on Day 2 without pretreatment with MMC
Total
n=15 Participants
Total of all reporting groups
Age, Continuous
67 years
STANDARD_DEVIATION 11.6 • n=5 Participants
62.7 years
STANDARD_DEVIATION 8.3 • n=7 Participants
65 years
STANDARD_DEVIATION 9.4 • n=5 Participants
Sex: Female, Male
Female
2 Participants
n=5 Participants
1 Participants
n=7 Participants
3 Participants
n=5 Participants
Sex: Female, Male
Male
7 Participants
n=5 Participants
5 Participants
n=7 Participants
12 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
9 Participants
n=5 Participants
6 Participants
n=7 Participants
15 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants

PRIMARY outcome

Timeframe: 30 days from last dose

Number of Participants with Treatment-emergent adverse events. The events for each cohort of dose of CVA21 only are pooled for the analysis.

Outcome measures

Outcome measures
Measure
CVA21
n=9 Participants
CVA21 was administered by intravesical instillation of one of 3 ascending dose levels or schedules
CVA21/Mitomycin C
n=6 Participants
Mitomycin C (MMC) was administered at 10 mg by intravesical instillation on Day 1. Four hours after instillation of MMC, CVA21 was administered by intravesical instillation of one of 2 ascending dose levels or schedules. Subjects received a second instillation of CVA21 alone on Day 2 without pretreatment with MMC.
Incidence of Dose-limiting Toxicities Treatment-related Adverse Events.
9 Participants
6 Participants

Adverse Events

CVA21

Serious events: 1 serious events
Other events: 9 other events
Deaths: 0 deaths

CVA21/Mitomycin C

Serious events: 0 serious events
Other events: 6 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
CVA21
n=9 participants at risk
CVA21 was administered by intravesical instillation of one of 3 ascending dose levels or schedules
CVA21/Mitomycin C
n=6 participants at risk
Mitomycin C (MMC) was administered at 10 mg by intravesical instillation on Day 1. Four hours after instillation of MMC, CVA21 was administered by intravesical instillation of one of 2 ascending dose levels or schedules. Subjects received a second instillation of CVA21 alone on Day 2 without pretreatment with MMC.
Infections and infestations
E. Coli urinary tract infection
11.1%
1/9 • Number of events 1 • 30 days. The analysis for each dose escalation cohort for CVA21 only was pooled as the numbers were so small. This resulted in an analysis showing 2 arms.
No SUSARs were reported for the VLA-012 study.
0.00%
0/6 • 30 days. The analysis for each dose escalation cohort for CVA21 only was pooled as the numbers were so small. This resulted in an analysis showing 2 arms.
No SUSARs were reported for the VLA-012 study.

Other adverse events

Other adverse events
Measure
CVA21
n=9 participants at risk
CVA21 was administered by intravesical instillation of one of 3 ascending dose levels or schedules
CVA21/Mitomycin C
n=6 participants at risk
Mitomycin C (MMC) was administered at 10 mg by intravesical instillation on Day 1. Four hours after instillation of MMC, CVA21 was administered by intravesical instillation of one of 2 ascending dose levels or schedules. Subjects received a second instillation of CVA21 alone on Day 2 without pretreatment with MMC.
Renal and urinary disorders
Hematuria
55.6%
5/9 • Number of events 5 • 30 days. The analysis for each dose escalation cohort for CVA21 only was pooled as the numbers were so small. This resulted in an analysis showing 2 arms.
No SUSARs were reported for the VLA-012 study.
66.7%
4/6 • Number of events 4 • 30 days. The analysis for each dose escalation cohort for CVA21 only was pooled as the numbers were so small. This resulted in an analysis showing 2 arms.
No SUSARs were reported for the VLA-012 study.
Renal and urinary disorders
Dysuria
55.6%
5/9 • Number of events 5 • 30 days. The analysis for each dose escalation cohort for CVA21 only was pooled as the numbers were so small. This resulted in an analysis showing 2 arms.
No SUSARs were reported for the VLA-012 study.
16.7%
1/6 • Number of events 1 • 30 days. The analysis for each dose escalation cohort for CVA21 only was pooled as the numbers were so small. This resulted in an analysis showing 2 arms.
No SUSARs were reported for the VLA-012 study.
Renal and urinary disorders
Pollakiuria
33.3%
3/9 • Number of events 3 • 30 days. The analysis for each dose escalation cohort for CVA21 only was pooled as the numbers were so small. This resulted in an analysis showing 2 arms.
No SUSARs were reported for the VLA-012 study.
16.7%
1/6 • Number of events 1 • 30 days. The analysis for each dose escalation cohort for CVA21 only was pooled as the numbers were so small. This resulted in an analysis showing 2 arms.
No SUSARs were reported for the VLA-012 study.
Renal and urinary disorders
Bladder discomfort
0.00%
0/9 • 30 days. The analysis for each dose escalation cohort for CVA21 only was pooled as the numbers were so small. This resulted in an analysis showing 2 arms.
No SUSARs were reported for the VLA-012 study.
16.7%
1/6 • Number of events 1 • 30 days. The analysis for each dose escalation cohort for CVA21 only was pooled as the numbers were so small. This resulted in an analysis showing 2 arms.
No SUSARs were reported for the VLA-012 study.
Renal and urinary disorders
Bladder disorder
11.1%
1/9 • Number of events 1 • 30 days. The analysis for each dose escalation cohort for CVA21 only was pooled as the numbers were so small. This resulted in an analysis showing 2 arms.
No SUSARs were reported for the VLA-012 study.
0.00%
0/6 • 30 days. The analysis for each dose escalation cohort for CVA21 only was pooled as the numbers were so small. This resulted in an analysis showing 2 arms.
No SUSARs were reported for the VLA-012 study.
Renal and urinary disorders
Bladder Pain
11.1%
1/9 • Number of events 1 • 30 days. The analysis for each dose escalation cohort for CVA21 only was pooled as the numbers were so small. This resulted in an analysis showing 2 arms.
No SUSARs were reported for the VLA-012 study.
0.00%
0/6 • 30 days. The analysis for each dose escalation cohort for CVA21 only was pooled as the numbers were so small. This resulted in an analysis showing 2 arms.
No SUSARs were reported for the VLA-012 study.
Renal and urinary disorders
Micturition urgency
11.1%
1/9 • Number of events 2 • 30 days. The analysis for each dose escalation cohort for CVA21 only was pooled as the numbers were so small. This resulted in an analysis showing 2 arms.
No SUSARs were reported for the VLA-012 study.
0.00%
0/6 • 30 days. The analysis for each dose escalation cohort for CVA21 only was pooled as the numbers were so small. This resulted in an analysis showing 2 arms.
No SUSARs were reported for the VLA-012 study.
Renal and urinary disorders
Urinary incontinence
11.1%
1/9 • Number of events 1 • 30 days. The analysis for each dose escalation cohort for CVA21 only was pooled as the numbers were so small. This resulted in an analysis showing 2 arms.
No SUSARs were reported for the VLA-012 study.
0.00%
0/6 • 30 days. The analysis for each dose escalation cohort for CVA21 only was pooled as the numbers were so small. This resulted in an analysis showing 2 arms.
No SUSARs were reported for the VLA-012 study.
Infections and infestations
Urinary tract infection enterococcal
22.2%
2/9 • Number of events 2 • 30 days. The analysis for each dose escalation cohort for CVA21 only was pooled as the numbers were so small. This resulted in an analysis showing 2 arms.
No SUSARs were reported for the VLA-012 study.
16.7%
1/6 • Number of events 1 • 30 days. The analysis for each dose escalation cohort for CVA21 only was pooled as the numbers were so small. This resulted in an analysis showing 2 arms.
No SUSARs were reported for the VLA-012 study.
Infections and infestations
Escherichia urinary tract infection
22.2%
2/9 • Number of events 2 • 30 days. The analysis for each dose escalation cohort for CVA21 only was pooled as the numbers were so small. This resulted in an analysis showing 2 arms.
No SUSARs were reported for the VLA-012 study.
0.00%
0/6 • 30 days. The analysis for each dose escalation cohort for CVA21 only was pooled as the numbers were so small. This resulted in an analysis showing 2 arms.
No SUSARs were reported for the VLA-012 study.
Infections and infestations
Urinary tract infection
0.00%
0/9 • 30 days. The analysis for each dose escalation cohort for CVA21 only was pooled as the numbers were so small. This resulted in an analysis showing 2 arms.
No SUSARs were reported for the VLA-012 study.
16.7%
1/6 • Number of events 1 • 30 days. The analysis for each dose escalation cohort for CVA21 only was pooled as the numbers were so small. This resulted in an analysis showing 2 arms.
No SUSARs were reported for the VLA-012 study.
Gastrointestinal disorders
Abdominal discomfort
11.1%
1/9 • Number of events 1 • 30 days. The analysis for each dose escalation cohort for CVA21 only was pooled as the numbers were so small. This resulted in an analysis showing 2 arms.
No SUSARs were reported for the VLA-012 study.
0.00%
0/6 • 30 days. The analysis for each dose escalation cohort for CVA21 only was pooled as the numbers were so small. This resulted in an analysis showing 2 arms.
No SUSARs were reported for the VLA-012 study.
Gastrointestinal disorders
Abdominal distension
11.1%
1/9 • Number of events 1 • 30 days. The analysis for each dose escalation cohort for CVA21 only was pooled as the numbers were so small. This resulted in an analysis showing 2 arms.
No SUSARs were reported for the VLA-012 study.
0.00%
0/6 • 30 days. The analysis for each dose escalation cohort for CVA21 only was pooled as the numbers were so small. This resulted in an analysis showing 2 arms.
No SUSARs were reported for the VLA-012 study.
Gastrointestinal disorders
Abdominal pain
0.00%
0/9 • 30 days. The analysis for each dose escalation cohort for CVA21 only was pooled as the numbers were so small. This resulted in an analysis showing 2 arms.
No SUSARs were reported for the VLA-012 study.
16.7%
1/6 • Number of events 1 • 30 days. The analysis for each dose escalation cohort for CVA21 only was pooled as the numbers were so small. This resulted in an analysis showing 2 arms.
No SUSARs were reported for the VLA-012 study.
Gastrointestinal disorders
Constipation
0.00%
0/9 • 30 days. The analysis for each dose escalation cohort for CVA21 only was pooled as the numbers were so small. This resulted in an analysis showing 2 arms.
No SUSARs were reported for the VLA-012 study.
16.7%
1/6 • Number of events 1 • 30 days. The analysis for each dose escalation cohort for CVA21 only was pooled as the numbers were so small. This resulted in an analysis showing 2 arms.
No SUSARs were reported for the VLA-012 study.
Gastrointestinal disorders
Diverticulum
11.1%
1/9 • Number of events 1 • 30 days. The analysis for each dose escalation cohort for CVA21 only was pooled as the numbers were so small. This resulted in an analysis showing 2 arms.
No SUSARs were reported for the VLA-012 study.
0.00%
0/6 • 30 days. The analysis for each dose escalation cohort for CVA21 only was pooled as the numbers were so small. This resulted in an analysis showing 2 arms.
No SUSARs were reported for the VLA-012 study.
Gastrointestinal disorders
Nausea
0.00%
0/9 • 30 days. The analysis for each dose escalation cohort for CVA21 only was pooled as the numbers were so small. This resulted in an analysis showing 2 arms.
No SUSARs were reported for the VLA-012 study.
16.7%
1/6 • Number of events 1 • 30 days. The analysis for each dose escalation cohort for CVA21 only was pooled as the numbers were so small. This resulted in an analysis showing 2 arms.
No SUSARs were reported for the VLA-012 study.
Gastrointestinal disorders
Toothache
11.1%
1/9 • Number of events 1 • 30 days. The analysis for each dose escalation cohort for CVA21 only was pooled as the numbers were so small. This resulted in an analysis showing 2 arms.
No SUSARs were reported for the VLA-012 study.
0.00%
0/6 • 30 days. The analysis for each dose escalation cohort for CVA21 only was pooled as the numbers were so small. This resulted in an analysis showing 2 arms.
No SUSARs were reported for the VLA-012 study.
Investigations
Blood urea increased
22.2%
2/9 • Number of events 2 • 30 days. The analysis for each dose escalation cohort for CVA21 only was pooled as the numbers were so small. This resulted in an analysis showing 2 arms.
No SUSARs were reported for the VLA-012 study.
0.00%
0/6 • 30 days. The analysis for each dose escalation cohort for CVA21 only was pooled as the numbers were so small. This resulted in an analysis showing 2 arms.
No SUSARs were reported for the VLA-012 study.
Investigations
Blood uric acid increased
22.2%
2/9 • Number of events 2 • 30 days. The analysis for each dose escalation cohort for CVA21 only was pooled as the numbers were so small. This resulted in an analysis showing 2 arms.
No SUSARs were reported for the VLA-012 study.
0.00%
0/6 • 30 days. The analysis for each dose escalation cohort for CVA21 only was pooled as the numbers were so small. This resulted in an analysis showing 2 arms.
No SUSARs were reported for the VLA-012 study.
Investigations
Blood bilirubin increased
11.1%
1/9 • Number of events 1 • 30 days. The analysis for each dose escalation cohort for CVA21 only was pooled as the numbers were so small. This resulted in an analysis showing 2 arms.
No SUSARs were reported for the VLA-012 study.
0.00%
0/6 • 30 days. The analysis for each dose escalation cohort for CVA21 only was pooled as the numbers were so small. This resulted in an analysis showing 2 arms.
No SUSARs were reported for the VLA-012 study.
Investigations
Blood glucose increased
11.1%
1/9 • Number of events 1 • 30 days. The analysis for each dose escalation cohort for CVA21 only was pooled as the numbers were so small. This resulted in an analysis showing 2 arms.
No SUSARs were reported for the VLA-012 study.
0.00%
0/6 • 30 days. The analysis for each dose escalation cohort for CVA21 only was pooled as the numbers were so small. This resulted in an analysis showing 2 arms.
No SUSARs were reported for the VLA-012 study.
Investigations
Lipase increased
11.1%
1/9 • Number of events 1 • 30 days. The analysis for each dose escalation cohort for CVA21 only was pooled as the numbers were so small. This resulted in an analysis showing 2 arms.
No SUSARs were reported for the VLA-012 study.
0.00%
0/6 • 30 days. The analysis for each dose escalation cohort for CVA21 only was pooled as the numbers were so small. This resulted in an analysis showing 2 arms.
No SUSARs were reported for the VLA-012 study.
Investigations
Neutrophil count increased
11.1%
1/9 • Number of events 1 • 30 days. The analysis for each dose escalation cohort for CVA21 only was pooled as the numbers were so small. This resulted in an analysis showing 2 arms.
No SUSARs were reported for the VLA-012 study.
0.00%
0/6 • 30 days. The analysis for each dose escalation cohort for CVA21 only was pooled as the numbers were so small. This resulted in an analysis showing 2 arms.
No SUSARs were reported for the VLA-012 study.
Investigations
White blood cell count increased
11.1%
1/9 • Number of events 1 • 30 days. The analysis for each dose escalation cohort for CVA21 only was pooled as the numbers were so small. This resulted in an analysis showing 2 arms.
No SUSARs were reported for the VLA-012 study.
0.00%
0/6 • 30 days. The analysis for each dose escalation cohort for CVA21 only was pooled as the numbers were so small. This resulted in an analysis showing 2 arms.
No SUSARs were reported for the VLA-012 study.
Investigations
White blood cells urine positive
11.1%
1/9 • Number of events 1 • 30 days. The analysis for each dose escalation cohort for CVA21 only was pooled as the numbers were so small. This resulted in an analysis showing 2 arms.
No SUSARs were reported for the VLA-012 study.
0.00%
0/6 • 30 days. The analysis for each dose escalation cohort for CVA21 only was pooled as the numbers were so small. This resulted in an analysis showing 2 arms.
No SUSARs were reported for the VLA-012 study.
General disorders
Fatigue
22.2%
2/9 • Number of events 2 • 30 days. The analysis for each dose escalation cohort for CVA21 only was pooled as the numbers were so small. This resulted in an analysis showing 2 arms.
No SUSARs were reported for the VLA-012 study.
0.00%
0/6 • 30 days. The analysis for each dose escalation cohort for CVA21 only was pooled as the numbers were so small. This resulted in an analysis showing 2 arms.
No SUSARs were reported for the VLA-012 study.
General disorders
Chills
11.1%
1/9 • Number of events 1 • 30 days. The analysis for each dose escalation cohort for CVA21 only was pooled as the numbers were so small. This resulted in an analysis showing 2 arms.
No SUSARs were reported for the VLA-012 study.
0.00%
0/6 • 30 days. The analysis for each dose escalation cohort for CVA21 only was pooled as the numbers were so small. This resulted in an analysis showing 2 arms.
No SUSARs were reported for the VLA-012 study.
General disorders
Influenza like illness
11.1%
1/9 • Number of events 1 • 30 days. The analysis for each dose escalation cohort for CVA21 only was pooled as the numbers were so small. This resulted in an analysis showing 2 arms.
No SUSARs were reported for the VLA-012 study.
0.00%
0/6 • 30 days. The analysis for each dose escalation cohort for CVA21 only was pooled as the numbers were so small. This resulted in an analysis showing 2 arms.
No SUSARs were reported for the VLA-012 study.
General disorders
Pyrexia
11.1%
1/9 • Number of events 1 • 30 days. The analysis for each dose escalation cohort for CVA21 only was pooled as the numbers were so small. This resulted in an analysis showing 2 arms.
No SUSARs were reported for the VLA-012 study.
0.00%
0/6 • 30 days. The analysis for each dose escalation cohort for CVA21 only was pooled as the numbers were so small. This resulted in an analysis showing 2 arms.
No SUSARs were reported for the VLA-012 study.
Metabolism and nutrition disorders
Hyperglycaemia
33.3%
3/9 • Number of events 3 • 30 days. The analysis for each dose escalation cohort for CVA21 only was pooled as the numbers were so small. This resulted in an analysis showing 2 arms.
No SUSARs were reported for the VLA-012 study.
16.7%
1/6 • Number of events 1 • 30 days. The analysis for each dose escalation cohort for CVA21 only was pooled as the numbers were so small. This resulted in an analysis showing 2 arms.
No SUSARs were reported for the VLA-012 study.
Metabolism and nutrition disorders
Decreased appetite
22.2%
2/9 • Number of events 2 • 30 days. The analysis for each dose escalation cohort for CVA21 only was pooled as the numbers were so small. This resulted in an analysis showing 2 arms.
No SUSARs were reported for the VLA-012 study.
0.00%
0/6 • 30 days. The analysis for each dose escalation cohort for CVA21 only was pooled as the numbers were so small. This resulted in an analysis showing 2 arms.
No SUSARs were reported for the VLA-012 study.
Blood and lymphatic system disorders
Leukocytosis
11.1%
1/9 • Number of events 1 • 30 days. The analysis for each dose escalation cohort for CVA21 only was pooled as the numbers were so small. This resulted in an analysis showing 2 arms.
No SUSARs were reported for the VLA-012 study.
0.00%
0/6 • 30 days. The analysis for each dose escalation cohort for CVA21 only was pooled as the numbers were so small. This resulted in an analysis showing 2 arms.
No SUSARs were reported for the VLA-012 study.
Blood and lymphatic system disorders
Thrombocytopenia
11.1%
1/9 • Number of events 1 • 30 days. The analysis for each dose escalation cohort for CVA21 only was pooled as the numbers were so small. This resulted in an analysis showing 2 arms.
No SUSARs were reported for the VLA-012 study.
0.00%
0/6 • 30 days. The analysis for each dose escalation cohort for CVA21 only was pooled as the numbers were so small. This resulted in an analysis showing 2 arms.
No SUSARs were reported for the VLA-012 study.
Nervous system disorders
Dizziness
0.00%
0/9 • 30 days. The analysis for each dose escalation cohort for CVA21 only was pooled as the numbers were so small. This resulted in an analysis showing 2 arms.
No SUSARs were reported for the VLA-012 study.
16.7%
1/6 • Number of events 1 • 30 days. The analysis for each dose escalation cohort for CVA21 only was pooled as the numbers were so small. This resulted in an analysis showing 2 arms.
No SUSARs were reported for the VLA-012 study.
Nervous system disorders
Headache
11.1%
1/9 • Number of events 1 • 30 days. The analysis for each dose escalation cohort for CVA21 only was pooled as the numbers were so small. This resulted in an analysis showing 2 arms.
No SUSARs were reported for the VLA-012 study.
0.00%
0/6 • 30 days. The analysis for each dose escalation cohort for CVA21 only was pooled as the numbers were so small. This resulted in an analysis showing 2 arms.
No SUSARs were reported for the VLA-012 study.
Musculoskeletal and connective tissue disorders
Arthralgia
11.1%
1/9 • Number of events 1 • 30 days. The analysis for each dose escalation cohort for CVA21 only was pooled as the numbers were so small. This resulted in an analysis showing 2 arms.
No SUSARs were reported for the VLA-012 study.
0.00%
0/6 • 30 days. The analysis for each dose escalation cohort for CVA21 only was pooled as the numbers were so small. This resulted in an analysis showing 2 arms.
No SUSARs were reported for the VLA-012 study.
Reproductive system and breast disorders
Genital discomfort
11.1%
1/9 • Number of events 1 • 30 days. The analysis for each dose escalation cohort for CVA21 only was pooled as the numbers were so small. This resulted in an analysis showing 2 arms.
No SUSARs were reported for the VLA-012 study.
0.00%
0/6 • 30 days. The analysis for each dose escalation cohort for CVA21 only was pooled as the numbers were so small. This resulted in an analysis showing 2 arms.
No SUSARs were reported for the VLA-012 study.
Skin and subcutaneous tissue disorders
Hyperhidrosis
11.1%
1/9 • Number of events 1 • 30 days. The analysis for each dose escalation cohort for CVA21 only was pooled as the numbers were so small. This resulted in an analysis showing 2 arms.
No SUSARs were reported for the VLA-012 study.
0.00%
0/6 • 30 days. The analysis for each dose escalation cohort for CVA21 only was pooled as the numbers were so small. This resulted in an analysis showing 2 arms.
No SUSARs were reported for the VLA-012 study.
Surgical and medical procedures
Skin neoplasm excision
11.1%
1/9 • Number of events 1 • 30 days. The analysis for each dose escalation cohort for CVA21 only was pooled as the numbers were so small. This resulted in an analysis showing 2 arms.
No SUSARs were reported for the VLA-012 study.
0.00%
0/6 • 30 days. The analysis for each dose escalation cohort for CVA21 only was pooled as the numbers were so small. This resulted in an analysis showing 2 arms.
No SUSARs were reported for the VLA-012 study.
Vascular disorders
Hypertension
0.00%
0/9 • 30 days. The analysis for each dose escalation cohort for CVA21 only was pooled as the numbers were so small. This resulted in an analysis showing 2 arms.
No SUSARs were reported for the VLA-012 study.
16.7%
1/6 • Number of events 1 • 30 days. The analysis for each dose escalation cohort for CVA21 only was pooled as the numbers were so small. This resulted in an analysis showing 2 arms.
No SUSARs were reported for the VLA-012 study.

Additional Information

Mark Grose

Viralytics

Phone: +1 905 593 2891

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place